Mortality and treatment at 12 and 24 months of follow up in patients in the bosentan cohort
| 12 months(N = 139) | 24 months(N = 139) | |
|---|---|---|
| *Includes one patient lost to follow up. | ||
| †Includes patients with missing information. | ||
| ‡Percentages are based on the total number of patients with sufficient observation time at the given time point. | ||
| Dead | 4 (2.9%)* | 13 (9.4%)* |
| Alive | 135 (97.1%) | 103 (74.1%) |
| Insufficient observation | – | 23 (16.5%) |
| Patients with sufficient observation time‡ | (n = 139) | (n = 116) |
| Bosentan alone | 121 (87%) | 87 (75%) |
| Bosentan + other treatment | 7 (5%) | 8 (7%) |
| Other or no treatment | 7 (5%)† | 8 (7%)† |
| Dead | 4 (3%)* | 13 (11%)* |